
Accuray’s Tomo® C Radiation Treatment Delivery System Approved by China’s NMPA
Accuray Incorporated (NASDAQ: ARAY) has announced a significant achievement as the Chinese National Medical Products Administration (NMPA) has approved the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system in China.
Approximately 50% of cancer patients are estimated to require radiation therapy. There are 2.2 million new cases of cancer diagnosed in China each year, and overall mortality has increased 30% in the last 20 years making it the number one cause of death in the country. A 2015 report estimated the Chinese market for radiation therapy devices at $3.8 billion and it was experiencing significant growth.
Accuray’s Tomo C platform is a radiation therapy system that incorporates helical imaging and radiation delivery. It offers fully-integrated treatment planning, centralized data management, and ultra-precise treatment delivery through patented beam-shaping technology. The system is designed to provide medical care teams with greater control over radiation dosage for precise targeting of tumors while minimizing exposure to healthy tissue. The Tomo C system is characterized by its unique architecture and high-speed multi-leaf collimator, allowing healthcare professionals to choose from a range of delivery modalities. This flexibility optimizes outcomes for standard radiation therapy indications such as breast, prostate, lung, and head and neck cancers. It is also suitable for complex treatments like total marrow irradiation.
Suzanne Winter, President, and CEO of Accuray, expressed her enthusiasm regarding this approval: “The NMPA approval of the Tomo C System represents a tremendous milestone for Accuray and the CNNC-Accuray joint venture. The availability of the new system will enable us to expand access to radiotherapy treatments to cancer patients needing care. Currently, the number of people requiring radiation treatments in China far outweighs the capacity for treatment. In fact, the number of systems that deliver radiation therapy is well below the World Health Organization recommendations.”